ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2026
New frontiers in O-MFS: omic-maxillofacial surgery toward a translational approach to patient care.
Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The integration of omics sciences into maxillofacial surgery marks a transformative step toward a new model of personalized and translational patient care. Recent advances in genomics, transcriptomics, and epigenomics are reshaping the understanding and management of head and neck squamous cell carcinoma (HNSCC), one of the most challenging malignancies in the maxillofacial region due to its biological heterogeneity and poor prognosis. Omics sciences offer unprecedented insight into the molecular landscape of these tumors, allowing the identification of specific biomarkers that predict patient outcomes and guide tailored surgical strategies. A landmark study by Ribeiro et al. demonstrated the clinical value of a nine-gene multi-omics signature capable of distinguishing HNSCC patients with markedly different survival rates, independent of metastasis status. This signature integrates copy number alterations, gene expression profiles, and methylation patterns linked to key cellular processes such as DNA repair, cytoskeletal dynamics, and immune response. The concept of "Omic-Maxillofacial Surgery" (O-MFS) envisions a future where molecular data complement anatomical, pathological, and functional criteria to refine surgical planning, intraoperative decision-making, and postoperative surveillance. Despite challenges related to data complexity, clinical validation, and cost, this emerging approach promises to revolutionize maxillofacial oncology by enabling more accurate patient stratification and truly personalized surgical care.
Indexed as
Identifiers
41109881What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.